NCT01286038View on ClinicalTrials.gov

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 6, 2011

Primary Completion Date

November 3, 2017

Study Completion Date

November 3, 2018

Conditions
Myelodysplastic Syndrome (MDS)Thrombocytopenia
Interventions
DRUG

Eltrombopag

In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01286038 - Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | Biotech Hunter | Biotech Hunter